These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 9442546)
61. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Hollander E; Kaplan A; Schmeidler J; Yang H; Li D; Koran LM; Barbato LM J Neuropsychiatry Clin Neurosci; 2005; 17(4):472-7. PubMed ID: 16387985 [TBL] [Abstract][Full Text] [Related]
62. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Mundo E; Bianchi L; Bellodi L J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005 [TBL] [Abstract][Full Text] [Related]
63. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Bastani B; Arora RC; Meltzer HY Biol Psychiatry; 1991 Jul; 30(2):131-9. PubMed ID: 1655071 [TBL] [Abstract][Full Text] [Related]
64. Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder. Altemus M; Murphy DL; Greenberg B; Lesch KP Am J Med Genet; 1996 Jul; 67(4):409-11. PubMed ID: 8837711 [TBL] [Abstract][Full Text] [Related]
65. Fluvoxamine approved for treating OCD in children. J Psychosoc Nurs Ment Health Serv; 2001 Jan; 39(1):11. PubMed ID: 11197991 [No Abstract] [Full Text] [Related]
66. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study. Feng B; Zhang ZJ; Zhu RM; Yuan GZ; Luo LY; McAlonan GM; Xu FZ; Chen J; Liu LY; Lv YY; Wong HK; Zhang Y; Zhu LX J Psychiatr Res; 2016 Sep; 80():30-37. PubMed ID: 27281260 [TBL] [Abstract][Full Text] [Related]
68. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Mundo E; Rouillon F; Figuera ML; Stigler M Hum Psychopharmacol; 2001 Aug; 16(6):461-468. PubMed ID: 12404554 [TBL] [Abstract][Full Text] [Related]
69. Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment. Monteleone P; Catapano F; Bortolotti F; Maj M Biol Psychiatry; 1997 Aug; 42(3):175-80. PubMed ID: 9232209 [TBL] [Abstract][Full Text] [Related]
70. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493 [TBL] [Abstract][Full Text] [Related]
71. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364 [TBL] [Abstract][Full Text] [Related]
72. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. Rausch JL; Hobby HM; Shendarkar N; Johnson ME; Li J J Clin Psychopharmacol; 2001 Apr; 21(2):139-42. PubMed ID: 11270909 [TBL] [Abstract][Full Text] [Related]
73. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. Denys D; van der Wee N; van Megen HJ; Westenberg HG J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187 [TBL] [Abstract][Full Text] [Related]
74. A review of pharmacologic treatments for obsessive-compulsive disorder. Kaplan A; Hollander E Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138 [TBL] [Abstract][Full Text] [Related]